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Abstract 
The growth and recurrence of a number of cancers is driven by a scarce population of cancer stem 
cells (CSCs), which are resistant to most current therapies. It has been shown previously that 
Natural Killer (NK) cells recognize human glioma, melanoma, colon and prostate CSCs in vitro. 
We herein show that human and mouse breast CSCs are also susceptible to NK cytotoxic activity in 
 2 
 
vitro. Moreover, CSC induced autologous NK cell activation and expansion in vivo, which correlate 
with the inhibition of CSC metastatic spread. These data suggest that NK cells control CSC 
metastatic spread in vivo and that their use in breast cancer therapy may well be fruitful. 
Keywords 
NK cells, CSCs, tumorspheres, metastasization, immunotherapy, breast cancer 
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Introduction 
The last century has seen a great deal of speculation as to the processes underlying the etiology of 
cancer and several theories have been put forward.
1, 2 
The fact that any cell exposed to genotoxic 
stress is able to generate a tumor has received general agreement.
3
 Meanwhile, stochastic influences 
have more recently been found to be major contributors to cancer development. They are nowadays 
often considered more important than either hereditary or external environmental factors. Most 
genomic changes occur simply by chance during DNA replication. Considering the number of 
mutations needed for malignant transformation, it appears highly plausible that these can only 
accumulate in long-lived cells, i.e. stem cells.
4
 
Cancer stem cells (CSCs) have recently been proposed as a key compartment of the tumor 
population.
5, 6
 Similarly to normal stem cells, CSCs are a slowly proliferating population which is 
able to self-renew and give rise to more differentiated cells that compose the bulk of a tumor.
7
 
CSCs have also been hypothesized to be a crucial factor in tumor recurrence, due to their intrinsic 
resistance to drugs and irradiation which often enables them to survive traditional therapies. 
Moreover, they have been demonstrated to be responsible for the hematological metastatic spread 
of solid tumors.
8
 
Therefore, the question of whether cells of the CSC phenotype and tumorigenic potential are 
common or rare within human cancers has fundamental implications for therapy.
9
 If tumorigenic 
cells are a small minority population, as suggested by the cancer stem cell theory,
10, 11
 improved 
anti-cancer therapies may be identified based on their ability to kill CSCs, rather than the bulk 
population of non-tumorigenic cancer cells.
12, 13
  
It is furthermore wise to explore whether effector immune cytotoxic cells (NK cells, CD8 T cells 
and γδ T cells) can be used to eliminate the tumor stem cell compartment in order to limit the CSC 
contribution to sustaining tumor progression. The low levels of MHC class I expression reported in 
CSCs hints at the low efficiency of CSC targeting by CD8 T lymphocytes.
14, 15
 However, the 
expression of ligands for NK activating receptors (NKG2D, NCR and DNAM-1)
15-17
 points to NK 
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cells and other innate immunity effector cells being able to recognize and eliminate CSCs. Indeed, 
recent data have demonstrated that human γδ T cells can target CSCs in vitro.18 
Human and murine NK cells are members of group 1 of Innate Lymphoid Cells.
19
 Their activation 
is regulated by activating receptors which recognize stress inducible ligands (NKG2D, DNAM-I) 
and the IgG Fc domain (CD16).
20 
NK cell tolerance is maintained by the engagement of inhibitory 
receptors which principally recognize MHC class I molecules (KIRs in humans, Ly49 receptors in 
mice).
21
 
Previous data have shown that NK cells selectively kill CSCs derived from human colon 
carcinoma,
15
 melanoma
16
 and glioblastoma,
17
 in mainly in vitro experiments. We herein describe in 
vitro and in vivo experiments which validate the NK cell targeting of breast tumor-derived CSCs 
using CSC-enriched tumorsphers
22 
derived from an ErbB-2
+
 murine breast cancer tumor cell line 
(TUBO),
23 
and murine and human triple negative breast cancer (TNBC) cell lines. 
Results and Discussion 
Tumorspheres derived from the murine ErbB2
+ 
tumor cell line, TUBO, were used to evaluate 
whether NK cells are able to recognize breast cancer derived CSCs. CSC enrichment in 
tumorspheres was confirmed via the increased percentage of cells that were positive for aldehyde 
dehydrogenase (ALDH) activity and for stem cell markers, Sca-1 and Thy1.1, as compared to 
TUBO parental cells (Fig. 1A and B, respectively), as has already been observed in previous 
reports.
22, 24
Moreover, tumorspheres showed increased in vitro self-renewal, with respect to TUBO 
cells in our own experiments. This is demonstrated by the higher number of cell clones generated 
by tumorspheres in a limiting dilution assay (Fig. 1C), confirming that they possess higher 
enrichment in CSCs than TUBO cells. Injecting TUBO and tumorspheres s.c. into BALB/c mice led 
to the observation that 1x10
3
 tumorsphere-derived cells gave rise to a fast growing palpable tumor 
in 100% mice, while the same number of TUBO cells induced a palpable tumor in only 66.7% of 
mice and did so with very slow kinetics (Fig. 1D, E). Moreover, mice injected with TUBO cells 
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exhibited significantly longer median survival times than mice injected with tumorsphere-derived 
cells (Fig. 1F). 
TUBO and tumorsphere susceptibility to autologous and allogeneic NK cell recognition was 
initially analyzed in vitro (Fig. 2). Highly purified autologous and allogeneic NK cells were 
obtained from the spleens of BALB/c and C57/BL6 mice, respectively. In both experimental 
settings, tumorspheres were recognized and killed with higher efficiency than TUBO cells (Fig. 2A, 
B). These observations are in agreement with those previously reported in other human solid tumor 
experimental systems.
15-17, 25
 In Figure 2, NK cells were activated with IL2 in vitro, whereas 
autologous and allogeneic NK cells were used as effectors without any activation in Table 1. 
Surprisingly, tumorspheres were selectively killed even when freshly explanted NK cells were used 
as effectors. It should be emphasized that the recognition of tumorspheres by non-activated murine 
NK cells is one of the few biological conditions in which non-activated NK cells can target tumor 
cells. 
In order to understand the molecular mechanisms that regulate selective NK mediated CSC 
elimination, we investigated the surface expression of inhibitory (H2-K
d
, H2-D
d
) and activating 
ligands (NKp46L, RAE, H60, PVR, Nectin-2) on tumorspheres and TUBO cells. Reduced H2-K
d
 
frequency and expression were observed together with an upregulation in PVR on the tumorsphere 
cell membrane (Fig. 3A, B). This latter finding confirms previous observations describing the 
crucial role that DNAM-1 ligands play in the NK recognition of CSCs.
26
 H2-D
d
 and the activating 
ligands for NKG2D and NCRs were expressed in similar amounts on both tumor cell types (Fig. 
S1A, B). The expression of NK activating and inhibitory ligands was evaluated using FACS in 
order to explore whether tumors and lung metastases induced in BALB/c mice via the s.c. or i.v. 
injection of either TUBO or tumorspheres maintain the differences in their expression rates. 
Interestingly, we have previously reported that tumorspheres maintain a prevalent CSC phenotype 
after in vivo injection
27
. As reported in Fig. 4, a lower frequency of H2-K
d
 and a higher frequency 
and expression of activating ligands, RAE, H60, PVR and Nectin-2, were observed in both the 
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tumorsphere generated tumors and metastases than in their TUBO generated analogues. Therefore, 
the immune phenotype that emerges from our data, which is characterized by a reduced number of 
MHC-I
+
 tumorspheres expressing higher levels of DNAM-1 activating ligands (PVR and Nectin-2), 
nicely correlates with the higher susceptibility of tumorspheres to NK cell recognition. However, 
we cannot exclude that in vivo other activating NK receptors besides DNAM-1 may play a role in 
the tumorsphere higher NK cells susceptibility, as suggested by the increased expression of RAE 
and H60 by tumorspheres  (Fig. 4A). 
The possible role of DNAM-1 receptors in driving tumorsphere recognition by NK cells was 
partially explored in functional experiments using DNAM-1 KO mice. Indeed, the data obtained 
suggests that NK cells derived from DNAM-1 KO mice display lower tumorsphere cytotoxicity 
recognition efficiency (Fig. S2A). 
It is worth noting that the in vitro NK cell recognition of breast cancer derived CSCs is not 
restricted to the TUBO model, as was also observed in CSCs derived from murine (4T1) and human 
(HCC-1806 and MDA-MB-231) TNBC cell lines. In fact, MHC-I expression decreased in 
tumorspheres derived from all of these cell lines (Fig. S3A and Fig. 5A, B). Moreover, an analysis 
of NK activating ligands, RAE, H60, PVR and Nectin-2, showed enhanced expression in 4T1-
derived tumorspheres over 4T1 cells (Fig. S3A). As reported in Figure 5C-F, allogeneic human NK 
cells, which had been isolated from healthy donors’ PBMC, recognized and killed tumorspheres 
generated from both HCC-1806 and MDA-MB-231 cells with higher efficiency than those 
generated by the two parental cell lines. Similar results were obtained on tumorspheres derived 
from 4T1 cells, which displayed higher susceptibility to autologous and allogeneic NK cell 
recognition than 4T1 cells (Fig. S3B). 
In order to evaluate any potential role that NK cells may play in controlling the hematological 
metastasization of TUBO cells and their derived tumorspheres in autologous conditions, BALB/c 
mice were divided into two different groups that received either TUBO or tumorsphere-derived 
cells i.v.. Each group was further divided into three subgroups in which the NK cell compartment 
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was manipulated by either depleting NK cells with a neutralizing antibody (TMβ1)28, 29 or by 
activating NK cell cytotoxicity with an interferon type I inducer (tilorone).
30
 
 
The third group of 
mice was treated with PBS as a control. Twenty-one days after cell injection, mice were sacrificed 
and lung metastases were counted and analyzed for size after H&E staining. As reported in Figure 
6, TUBO cell injection gave rise to a higher number of lung metastases in the control groups than in 
mice injected with tumorspheres (Fig. 6A, B). Moreover, the metastasis occupied lung surface was 
larger in mice injected with TUBO than in mice injected with tumorspheres (Fig. 6 D-F), suggesting 
that the NK cell-mediated elimination of CSCs is more pronounced here than in TUBO cells. NK 
cell depletion led to an increased number of lung metastases in TUBO, as well as in tumorsphere, 
injected mice, while NK cell activation by tilorone furnished a beneficial effect by limiting the lung 
metastatic spread in both experimental groups (Fig. 6A, B). It can therefore be stated that NK cells 
control the spread of both cell types in vivo. However, an analysis of the relative NK cell capability 
to control the metastatic spread of the bulk tumor population and/or CSCs revealed that NK 
manipulation had a stronger effect on tumorsphere metastatic spread (Fig. 6C), confirming the 
importance of NK cells in killing CSCs. This is confirmed by the observation that neither TMβ1 nor 
tilorone exert any effect on the amount of lung surface occupied by TUBO metastases, while they 
both significantly modify the area occupied by tumorsphere metastases (Fig. 6D-F). It should be 
noted that tumorspheres injected s.c. showed higher tumorigenicity than injected TUBO cells. We 
can speculate that this difference may reflect the different activation mechanisms that NK cells 
depend on in the blood and lungs, as reported in BL6 mice for NK cell in vivo control of the 
melanoma spread in the peritoneum and lung.
31
  
To understand whether the contrasting findings observed after the intravenous infusion of tumor 
cells were actually due to differences in NK cells, we analysed their expansion and activation in 
BALB/c mice injected s.c. and i.v. with either TUBO or tumorspheres, while a further group was 
left untreated. Mice injected i.v. were sacrificed 21 days after challenge while those injected s.c. 
were sacrificed when the tumor reached 5 mm in mean diameter. Blood, lung and tumor NK cell 
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frequencies and activation markers were analyzed. In the blood, CD49b
+
 NK cell frequency 
increased in the group that received tumorspheres i.v., as compared to all other groups (Fig. 7). 
Moreover, a higher frequency of circulating CD69
+
 NK cells was found in mice injected with 
tumorspheres, whether i.v. or s.c., as compared to other groups (Fig. 7). A detailed analysis of the 
different NK cell compartments in the blood of mice injected i.v. with either TUBO or 
tumorspheres was performed and is reported in Figure S4. It is worth noting that tumorsphere 
injection did not induce the expansion of T cell subsets (Fig. S5). The i.v. challenge with breast 
cancer derived CSCs thus selectively induced the expansion of the activated NK cell compartment, 
as previously reported in in vitro co-culture experiments conducted using autologous NK cells and 
human colon adenocarcinoma derived CSCs.
15
 However, the lack of Ly49H
+
 in BALB/c mice 
prevented us from better defining NK cell expansion, i.e. the NK cell memory subset associated 
with MCMV infected mice.
32
 
An analysis of the NK cell population infiltrating lung metastases and s.c. tumors revealed that the 
highest frequency of NK cells was observed in the lungs of mice injected i.v. with tumorspheres 
(Fig. 8 C, E). Interestingly, the NK population was more abundant in lung metastases than in s.c. 
tumors (Fig. 8 A-E) in both mice injected with TUBO and tumorspheres. The evaluation of NK 
activation displayed a higher percentage of CD69
+
 cells among the NK cells present in both lung 
metastases and the tumors of mice injected with tumorspheres than in TUBO-injected mice (Fig. 8 
A-E).  
In conclusion, our data show that in vivo murine breast cancer tumorspheres induce NK cell 
compartment expansion and promote their activation. Moreover, the in vivo manipulation of NK 
cell response affects the capability of tumorspheres to undergo lung metastatic spread. It has 
recently been reported that human ALDH
+
 CSCs, derived from human breast cancer, escape NK 
recognition by down regulating NKG2D ligands, thanks to the expression of miR20a.
33 
Our data in 
mice expand this finding and indicate that not all breast cancer derived CSCs are resistant to NK 
cell cytotoxic attack. 
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Our data corroborate previous in vitro observations obtained using human solid tumors and related 
CSCs,
12-14
 and strongly suggest that NK cells should be considered a potential useful tool in therapy 
protocols that aim to target the tumor CSC compartment.  
Material and Methods 
Cell lines 
ErbB2
+ 
murine breast tumor parental TUBO cells were cultured in DMEM 20% FBS.
34
 Murine 
(4T1) and human (HCC-1806 and MDA-MB-231) breast cancer parental cells were purchased from 
ATCC (LCG Standards) and cultured in RPMI plus 10% FBS or DMEM 10% FBS, respectively. 
Tumorspheres were generated by culturing TUBO, 4T1, MDA-MB-231 and HCC-1806 cells in 
ultra-low attachment flasks (Sigma-Aldrich) in DMEM-F12 supplemented with 0,4% bovine serum 
albumin (Sigma-Aldrich), 20 ng/ml basic Fibroblast Growth Factor (bFGF, Peprotech), 20 ng/ml 
Epidermal Growth Factor (EGF, Sigma-Aldrich) and 5 g/ml insulin (Sigma-Aldrich). They were 
propagated in vitro up to the third passage (P3, hereafter referred as tumorspheres), as previously 
described.
24 
In Vivo Treatments 
BALB/c and C57/BL6 mice were bought from Charles River Laboratories, maintained at the 
Molecular Biotechnology Center, University of Turin and treated in accordance with University 
Ethical Committee and European guidelines under Directive 2010/63.  
Primary s.c. tumors were induced by injecting the flank of female BALB/c mice with either 1x10
4
 
TUBO or tumorsphere-derived cells (n=6 for both conditions). Tumor growth was monitored 
weekly by caliper and reported as the mean of two perpendicular diameters (mm). Mice were 
sacrificed for ethical reasons when tumors reached 10 mm mean diameter.
35, 36
 Lung metastases 
were induced by injecting BALB/c mice i.v. with either 5x10
4 
TUBO or tumorsphere-derived cells. 
Each group was further divided into three subgroups (n=5 mice each) in which mice were either 
treated per os with tilorone (200 µg, Sigma-Aldrich) the day before cell challenge and then every 3 
days, treated i.v. with an anti-mouse-TMβ1 monoclonal antibody (200 µg, Mabtech) the day before 
 10 
 
cell injection and then every 7 days, or finally treated with PBS (as control). Twenty-one days after 
cell injection, blood was collected and mice were sacrificed in order to analyze lung metastasis 
formation and immune infiltrate both by FACS and histological analysis. Lungs were removed, 
fixed in 4% formaldehyde solution, cut into small pieces, paraffin-embedded, sectioned and 
haematoxylin and eosin (H&E) stained.
37
 Micrometastases were counted on a Nikon SMZ1000 
stereomicroscope (Amsterdam, Netherlands), their dimensions measured using ImageJ software and 
reported as the ratio between the area occupied by metastases and total lung area, as previously 
described.
19,38 
DNAM-1 KO mice
39
 were kindly provided by M Colonna Washington University Medical School, 
St Louis, MO. These mice and C57/BL6 mice were housed under specific pathogen–free conditions 
at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institute. Experiments 
were performed according to governmental and institutional guidelines and regulations were 
approved by the local ethical committee (North Stockholm District Court). 
Tumor and lung dissociation for FACS analysis 
For the phenotypic analysis, fresh primary tumor specimens of 5 mm mean diameter and lungs from 
BALB/c mice injected either s.c. or i.v. with TUBO or tumorspheres were finely minced with 
scissors and then digested by incubation with 1 mg/mL collagenase IV (Sigma Aldrich) in RPMI-
1640 (Life Technologies) at 37°C for 1 h in an orbital shaker. After washing in PBS supplemented 
with 2% fetal calf serum (GIBCO), the cell suspension was incubated in erylise buffer (155 mM 
NH4Cl, 15.8 mM Na2CO3, 1 mM EDTA, pH 7.3) for 10 min at RT. After washing in RPMI-1640 
supplemented with 10% FBS, the cell suspension was passed through a 70-µm pore cell strainer, 
centrifuged at 1400 rpm for 10 min and re-suspended in erylise buffer. Cells were collected, 
washed, re-suspended in PBS, treated with Fc-receptor blocker and stained for FACS analysis.
40, 41
 
Flow cytometry 
 11 
 
Cells derived from tumors and metastases, parental cells and tumorspheres harvested after 5 days of 
culture were washed in PBS supplemented with 0.2% BSA and 0.01% sodium azide (Sigma-
Aldrich) and stained as previously described,
42, 43
 with the following antibodies: Alexa Fluor647-
conjugated anti-Stem Cell Antigen (Sca)-1, allophycocyanin (APC)/Alexa Fluor780-conjugated 
anti-Thy1.1, FITC HLA-I clone w6/32 (BioLegend), FITC-conjugated anti-H2-K
d
, FITC-
conjugated anti-H2-D
d
 (Becton Dickinson) PE-conjugated H60 (R&D), pan RAE1-FITC (R&D), 
Nectin-2-APC (R&D) or with mouse NCR1-Ig (10 μg/ml) followed by Alexa Fluor 647 donkey 
anti-human Ig, kindly provided by Prof. F. Colucci, Cambridge University, UK. The ALDEFLUOR 
assay was performed to evaluate aldehyde dehydrogenase (ALDH) activity according to 
manufacturer’s instructions (Stem Cell Technologies, Vancouver, Canada). Cells were analyzed on 
a CyAnADP Flow Cytometer, using Summit 4.3 software (Beckman Coulter). Data were evaluated 
using FlowJo (Mac-Version 9.3.1; Treestar US, Ashland, OR) or Summit 4.3 software. 
Clonal formation assay 
TUBO cells and tumorspheres were plated at 1 cell/well in 96-well plates or in 96-well ultra-low 
attachment plates, containing 150 μl of epithelial or tumorsphere medium, respectively. The number 
of TUBO or tumorsphere clones generated after 7 days of culture was evaluated and reported as 
number of clones generated for every 100 single cells seeded. 
NK cell isolation 
To isolate NK cells, spleens were collected from 8 week-old female BALB/c and C57/BL6 mice 
(either treated 1 day before sacrifice with 200 µg tilorone per os, Sigma-Aldrich, or left untreated), 
and mashed in order to obtain splenocytes. For experiments with DNAM-1-KO and C57/BL6 mice, 
animals were treated i.p. with 100µg poly-I:C two days prior to NK cell isolation. Enriched NK 
cells were isolated from the separated splenocytes using murine NK Cell Isolation Kit II (Miltenyi 
Biotec) according to manufacturer’s instructions. NK cells were cultured overnight in RPMI 10% 
FBS and 1% Penicillin/Streptomycin, either with or without 200 U/ml IL-2 (Peprotech). For human 
NK cells, blood was obtained from healthy donors and peripheral blood lymphocytes were isolated 
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by Biocoll separating solution (Biochrom AG) density gradient centrifugation. Enriched NK cells 
were isolated from the separated PBMCs using the NK cell isolation kit (Miltenyi Biotec) according 
to manufacturer’s instructions. NK cells were cultured overnight in RPMI 10% FBS and 1% 
Penicillin/Streptomycin. The purity of isolated NK cells was > 95%, as assayed by flow cytometry. 
Cytotoxicity assays 
Cytotoxic assays were performed using fluorescent 5,6-carboxy-fluorescein-diacetate (CFDA) 
according to a protocol described elsewhere.
44
 Briefly, target cells were labeled with CFDA-mixed 
isomers (Invitrogen) and then with purified autologous and allogeneic NK effector cells at different 
Effector:Target (E:T) ratios. The incubation was performed in 96-well U-bottom plates at 37° C in a 
humidified 5% CO2 incubator for 3 h. The specific lysis of target cells was analyzed by flow 
cytometry (FACS CantoII, BD Pharmingen) and calculated as follows: % of specific lysis = (CT-
TE)/CT x 100, where CT indicates the mean number of fluorescent target cells in control tubes and 
TE indicates the mean number of fluorescent cells in target plus effector tubes. Data were evaluated 
using FlowJo (Mac-Version 9.3.1; Treestar US, Ashland, OR). 
NK cell immunophenotype 
Lymphocytes from the blood of mice were washed twice in PBS and then incubated with erylise 
buffer (155mM NH4Cl, 15.8mM Na2CO3, 1mM EDTA, pH 7.3) for 10 minutes at room 
temperature, washed in PBS and incubated with a purified anti-mouse CD16/CD32 (BD 
Pharmingen) for 10 minutes at room temperature. These cells and cells obtained from tumors and 
metastases were washed with PBS and then labeled for 30 minutes at 4° C with the following 
antibodies: FITC-conjugated anti-CD49b/DX5, APC/Cy7-conjugated anti-CD3, PE-conjugated 
anti-DNAM-I, APC-conjugated anti-NKp46, PerCp/Cy5.5-conjugated anti-CD69, Pacific Blue-
conjugated anti-LY49a (all from BioLegend), PE/Cy7-conjugated anti-NKG2D (eBioscience), PE-
conjugated anti-5E6 (BD). Cells were analyzed on a CyAnADP Flow Cytometer, using Summit 4.3 
software (Beckman Coulter). Data were evaluated using either FlowJo (Mac-Version 9.3.1; Treestar 
US, Ashland, OR) or Summit 4.3 software. 
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.0 Software. Either the unpaired 
Student’s t test and ANOVA Analysis or the Mann-Whitney test were used for non-parametric 
distributions to determine significance. Differences in tumor incidence and survival were analyzed 
using Mantel-Cox log-rank tests. A p value ≤ 0.05 was considered significant. * p ≤ 0.05; ** p ≤ 
0.01; ***p ≤ 0.001. 
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Table 1. NK cells in vitro killing without prior activation. TUBO, tumorsphere and yac-1 
susceptibility to NK cells without any activation 
 NK cell killing from BALB/C mice NK cell killing from C57/BL6 mice 
TUBO Tumorsphere
s 
Yac-1 TUBO Tumorsphere
s 
Yac-1 
E:T 
rati
o 
12:
1 
6:
1 
3:
1 
12:
1 
6:1 3:
1 
12:
1 
6:
1 
3:
1 
12:
1 
6:
1 
3:
1 
12:
1 
6:1 3:1 12:
1 
6:
1 
3:
1 
1° 
exp 
15 3 0 38 25 10 65 46 22 15 10 7 45 24 18 60 36 12 
2° 
exp 
12 0 0 25 5 1 71 53 31 10 8 0 43 23 10 65 46 17 
3° 
exp 
2 0 0 15 7 0 59 41 20 5 0 0 21 5 0 51 32 5 
 20 
 
 
 21 
 
Figure 1. Tumorsphere characterization. (A) Representative FACS dot plots showing ALDH 
activity in TUBO and tumorspheres, measured using the Aldefluor reagent (right panels). To define 
the ALDH
+
 gate, cells were stained with the Aldefluor reagent in the presence of the ALDH 
inhibitor DEAB (left panels). (B) Representative FACS dot plots showing the expression of Sca-1 
and Thy1.1 in TUBO and tumorspheres. Numbers show the percentage of cells in each region. (C) 
Capability of TUBO and tumorspheres to give rise to cell clones in a limiting dilution assay. The 
graph shows the mean ± SEM of the number of clones generated every 10
2
 single cells seeded; data 
are from three independent experiments. (D-F) Tumor growth (D), incidence (E) and Kaplan–Meier 
survival (F) curves of BALB/c mice s.c. injected with 1x10
3
 TUBO or tumorsphere-derived cells. 
Differences in mean tumor diameters were calculated using the Student’s t test, while differences in 
tumor incidence and survival were performed using the Mantel-Cox log-rank test. * p<0.05; ** p< 
0.01; *** p ≤ 0.001. 
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Figure 2. TUBO and tumorsphere susceptibility to NK cells. (A) A representative cytotoxicity 
assay, performed by culturing Yac-1 (triangle), TUBO cells (circles) and tumorspheres (squares) 
with autologous (from BALB/c, left panel) and allogeneic (from C57/BL6, right panel) splenocytes. 
NK cells were used at different E:T ratios, as reported on the X axes. (B) A statistical analysis of 
the data obtained from 5 independent cytotoxicity experiments at 3 different E:T ratios, with 
autologous NK cells (upper panel) and allogeneic NK cells (lower panel) against TUBO (grey bar) 
and tumorspheres (black bar). The mean ± SEM of the lysis (%) are reported. * p ≤ 0.05;  ** p ≤ 
0.01, Student's t test. 
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Figure 3. Phenotypic characterization of TUBO and tumorspheres. (A) A representative 
experiment showing the expression levels of the MHC class I (H2-K
d
) and the PVR molecules on 
the cell surface of TUBO (grey) and tumorspheres (black). Filled histograms represent specific 
staining while open histograms represent the background of isotype controls. (B) Statistical analysis 
of the data obtained from 6 different experiments as a percentage of positive cells and mean 
fluorescence intensity (MFI) of H2-K
d 
and PVR on TUBO (grey bar) and tumorspheres (black bar). 
* p ≤ 0.05;  ** p ≤ 0.01, Student's t test. 
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Figure 4. NK cell ligand expression on TUBO and tumorspheres ex vivo. Mean ± SEM of the 
percentage of positive cells (A) and of MFI (B) of H2-K
d
, PVR, H60, Rae-1 and Nectin-2, on 
TUBO (grey bar) and tumorspheres (black bar) injected either s.c. (tumor) or i.v. (lung) into 
BALB/c mice, from three different experiments. * p ≤ 0.05;  ** p ≤ 0.01, *** p ≤ 0.001, Student's t 
test. 
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Figure 5. Phenotypic characterization and susceptibility to NK cells of HCC-1806 and MDA-
MB-231 cells and their derived tumorspheres. (A, B) FACS analysis of the expression of the 
HLA-I molecules on HCC-1806 (A) and MDA-MB-231 (B) parental cells and tumorspheres. Filled 
histograms represent specific staining while open histograms represent the background of isotype 
controls. Graphs show the statistical analysis of the data obtained from 3 independent experiments 
as a percentage of positive cells and MFI of HLA-I on parental cells (grey bar) and tumorspheres 
(black bar). (C, D) A representative cytotoxicity assay performed by co-culturing HCC-1806 (C) 
and MDA-MB-231 (D) parental cells (circles) and tumorspheres (squares) with allogeneic 
lymphocytes. NK cells were used at different E:T ratios as reported on the X axes. (E, F) Means ± 
SEM of the percentage of lysis obtained from 3 independent cytotoxicity experiments at two 
different E:T ratios, with allogeneic NK cells against HCC-1806 (E) and MDA-MB-231 (F) 
parental cells (grey bar) and derived tumorspheres (black bar). * p ≤ 0.05;  ** p ≤ 0.01, Student's t 
test. 
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Figure 6. NK cells control lung metastasization. Number (A, B, C) and area (D, E, F) of lung 
metastases observed in BALB/c mice injected i.v. with either TUBO (A, D) or tumorspheres (B, E), 
and treated with either PBS (control), TMβ1 or tilorone. (C, F) Ratios between the number (C) and 
the area (F) of lung metastases of treated groups and their relative controls. Graphs show means ± 
SEM from 3 independent experiments. * p ≤ 0.1, ** p ≤ 0.01; *** p ≤ 0.001, Student's t test.  
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Figure 7. NK cell frequency in TUBO and tumorsphere challenged mice. FACS analysis of NK 
cells in the blood of BALB/c mice challenged either i.v. or s.c. with either TUBO (A,B) or 
tumorspheres (C,D) or left untreated (E), performed 21 days after i.v. cell challenge or when s.c. 
tumors measured 5 mm mean diameter. (A-E) Representative dot plots of the CD3
-
CD49b
+
 (left 
panels) and the CD69
+
CD3
-
CD49b
+
 (right panels) populations. (F,G) Statistical analysis of the data 
cumulated from 3 independent experiments on the frequencies of NK cells in mice challenged 
either i.v. or s.c. with TUBO (grey bar) and tumorspheres (black bar) or left untreated (UT). * p ≤ 
0.05, ** p ≤ 0.01; *** p ≤ 0.001, Student's t test. 
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Figure 8. NK cell frequency in tumors and metastases of TUBO and tumorsphere challenged 
mice. FACS analysis of NK cells in TUBO (A,B), tumorspheres (C,D) metastases (A,C) and tumors 
(B,D) generated in BALB/c mice challenged either i.v. or s.c., performed 21 days after i.v. cell 
challenge or when s.c. tumors measured 5 mm in mean diameter. (A-D) Representative dot plots of 
the CD3
-
CD49b
+
 (left panels) and the CD69
+
CD3
-
CD49b
+
 (right panels) populations. (E) Statistical 
analysis of the data cumulated from 3 independent experiments on the frequencies of NK cells in 
mice challenged either i.v. or s.c. with TUBO (grey bar) and tumorspheres (black bar). * p ≤ 0.05, 
** p ≤ 0.01, Student's t test. 
